Newer Formulations of Risperidone: Remarks About Risperidone ISM®.

Abstract

Clark I, Taylor D. Newer formulations of risperidone: role in the management of psychotic disorders. CNS Drugs. 2020;34:841–52. CAS Article Google Scholar Yapar E, Inal O, Ozkan Y, Baykara T. Injectable in situ forming microparticles: a novel drug delivery system. Trop J Pharm Res. 2012;11(2):307–18. Article Google Scholar Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci. 2009;36(4–5):524–31. CAS Article Google Scholar Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur J Pharm Sci. 2008;34(2–3):164–72. CAS Article Google Scholar Carabias L, Llaudo J, Ayani I, Martinez-Gonzalez J, Litman R, Gutierro I. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2017;33(2):79–877. Article Google Scholar Llaudo J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323–31. Article Google Scholar ROVI. ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union. 2020. https://www.rovi.es/sites/default/files/Doria%20validation_Press%20release_0.pdf. Accessed 25 Aug 2020. Laffont C, Gomeni R, Zheng B, et al. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol. 2015;55(1):93–103. CAS Article Google Scholar Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25:829–45. CAS PubMed Google Scholar Download references Medical Department, Laboratorios Farmaceuticos ROVI, S.A., Calle Alfonso Gomez, 45A, 28037, Madrid, Spain Lourdes Anta R&D Department, Laboratorios Farmaceuticos ROVI, Granada, Spain Elena Mata & Lourdes Ochoa Diaz de Monasterioguren You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar Correspondence to Lourdes Anta. No funding was received for the preparation of this letter. Lourdes Anta, Elena Mata, and Lourdes Ochoa Diaz de Monasterioguren are employees of Laboratorios Farmaceuticos ROVI, S.A., the sole developer of Risperidone ISM®. Not applicable. Not applicable. Not applicable. Not applicable. Not applicable. Not applicable. Reprints and Permissions Anta, L., Mata, E. & Ochoa Diaz de Monasterioguren, L. Newer Formulations of Risperidone: Remarks About Risperidone ISM®. CNS Drugs (2020). https://doi.org/10.1007/s40263-020-00762-0 Download citation Published: 05 September 2020 DOI: https://doi.org/10.1007/s40263-020-00762-0